Cellectar Biosciences, Inc. — Form 8-K
Filed July 10, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 24/100
What the filing says
Cellectar amended its 2021 Stock Incentive Plan effective March 4, 2021, establishing a maximum pool of 2,306,666 shares available for future equity awards (options, RSUs, performance shares, etc.) to employees, directors, and consultants, plus any shares that roll back from prior 2015 and 2006 plans. The filing documents the plan's mechanics—vesting terms, exercise prices, change-of-control provisions—but discloses no new grants, exercises, or material transactions. This is the amended plan document itself, not notice of a specific award or transaction.
Why this rating
Routine equity plan amendment. Share pool (2.3M) is ~6% of current market cap ($12.8M); material as dilution but standard governance; no new cash outflow, new employee, or business change disclosed.
See more from July 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.